NEWS: SEPTEMBER 2003

-9/30/2003-

Press Release: Guava Technologies Inc, a biotechnology company focused on providing comprehensive cell analysis at the benchtop, and the Department of Chemical Engineering at the University of Birmingham in the UK today announced they have formed a strategic research alliance to study apoptosis, or programmed cell death. To read press release click here.

Dyax Corp. and MedImmune Inc sign non-exclusive license for Dyax's proprietary antibody phage display libraries for of therapeutic antibody discovery research. To read article click here. Biotage Inc., a division of Dyax Corp., has a broad variety of purification systems for drug discovery. To find a review of Biotage's purification systems here at CombiChem Lab click here.

ArQule Inc. initiates clinical safety trials of its investigational small-molecule anti-cancer drug CO-501. To read article click here. ArQule Inc provides services for combinatorial chemistry and drug discovery. For a review of ArQule's discovery services here at CombiChem Lab click here.

Indevus Pharmaceuticals Inc. publishes positive Phase II clinical trial results of its cannabinoid compound IP 751 for the treatment of chronic neuropathic pain. To read article click here.

FDA gives fast-track status to Pharmos Corp.'s Dexanabinol for neuroprotective brain damage. To read article click here.

Oxigene Inc. initiates Phase I/II trials of Combretastatin A4 Prodrug (CA4P) in combination with antibody A5B7 for advanced colorectal cancer treatment. To read article click here.

deCODE genetics Inc identifies gene that predisposes obesity or slimness in humans. To read article click here.

Protein Design Labs Inc. (PDL) agrees to pay Roche $80 million for exclusive rights to develop Zenapax®. To read article click here.

Elan Corp.'s NanoSystems division and Bristol-Myers Squibb Company sign NanoCrystal technology license agreement. To read article click here.

VaxGen Inc. wins three-year $80.3 million contract from the National Institute of Allergy and Infectious Diseases (NIAID) for the development of its anthrax vaccine candidate rPA102. To read article click here.

-9/29/2003-

Chemical Diversity Labs Inc. (ChemDiv) and Mpex Pharmaceuticals Inc. sign compound-library agreement where CDL will provide Mpex with a 100,000 small-molecule diverse library for antibacterial drug discovery research. To read article click here. Chemical Diversity Labs Inc. (ChemDiv) offers diverse compound libraries and services for drug discovery research. For a review of ChemDiv's compound libraries and services here at CombiChem Lab click here and here, respectively.

Researchers at the Fisher Center for Research on Alzheimer's Disease at The Rockefeller University in New York City find that cancer drug kinase inhibitor Gleevec® ((Imatinib Mesylate, Glivec®, STI-571, or CGP57148B) lowers production of beta-amyloid and it could also play a key role in the treatment of Alzheimer's disease. To read article click here.

Nabi Biopharmaceuticals initiates Phase III clinical trials of StaphVax for infection prevention in patients with kidney disease. To read article click here.

Epimmune Inc. wins five-year $16.7 million contract from the National Institute of Allergy and Infectious Diseases (NIAID) for the development of an HIV vaccine. To read article click here.

Incara Pharmaceuticals Corporation receives U.S. patent 6,583,132 entitled "Oxidant Scavengers." To read article click here.

ZymoGenetics Inc. and Serono SA initiate Phase I clinical trials of TACI-Ig for lupus and rheumatoid arthritis treatment. To read article click here.

-9/26/2003-

SIGA Technologies Inc. and Pharmaceuticals AB form anti-infective drug discovery research collaboration for potential biowarfare agents. To read article click here.

Schering AG's cancer drug Zevalin recommended for approval in Europe. To read article click here.

-9/25/2003-

Press Release: Available from Viscotek, the leader in multiple detection characterisation of synthetic and natural polymers, the GPCmaxTM is the first fully featured GPC solvent /sample delivery system at an affordable price. To read press release click here.

Discovery Partners International Inc. (DPII) and AstraZeneca U.K. sign licensing agreement on Discovery Partners' gene expression profiling technology. To read article click here. DPII has 2 subsidiaries, ChemRx and IRORI, to provide support to drug discovery. ChemRx offers a diverse set of services for combinatorial chemistry and drug discovery. For a review of ChemRx's services here at CombiChem Lab click here. IRORI offers its radio-frequency tagged product line for combinatorial chemistry. For a review on IRORI's Accutag system here at CombiChem Lab click here.

Human Genome Sciences Inc.'s experimental anti-inflammatory drug Repifermin fails clinical trials In patients with chronic venous ulcers and it will not be further developed. To read article click here.

Intermune Inc. appoints Daniel Welch as President and CEO. To read article click here.

-9/24/2003-

Tripos Inc. signs agreement with Bristol-Myers Squibb Co. to integrate Tripos' FormsBUILDER™ technology into Bristol-Myers Squibb's SMART-IDEA application. To read article click here. Tripos Inc. provides a suite of software tools for combinatorial chemistry and drug discovery. For a review of Tripos' software tools here at CombiChem Lab click here.

FDA advisory panel backs Forest Laboratories Inc.'s drug Namenda (Memantine hydrochloride) for the treatment of Alzheimer's disease. To read article click here.

Lexicon Genetics Incorporated completes the physiological function analysis of more than 1,250 genes opening the doors for more than 20 drug discovery programs. To read article click here.

Johnson & Johnson Pharmaceutical Research & Development signs agreement with Affymetrix Inc. to access Affymetrix's new GeneChip® HighThroughputArray (HTA) Human Genome U133 Array platform. To read article click here.

Aeterna Laboratories Inc.'s drug Neovastat fails Phase III clinical trials for renal cell carcinoma treatment. To read article click here.

Boehringer Ingelheim Pharmaceuticals Inc. to expand its facilities in Ridgefield and Danbury Connecticut with a $400 - $500 million dollar investment. To read article click here.

American Pharmaceutical Partners Inc.'s cancer drug Abraxane found to be less toxic and more effective than Taxol in late-stage human tests. To read article click here.

-9/23/2003-

Press Release: The OmniSEC Copolymer module from Viscotek, the leader in multiple detection characterisation of synthetic and natural polymers, is the latest addition to the market leading multifunctional GPC/ SEC software. To read press release click here.

Accelrys Inc. to embed Oracle® technology into Accelrys' Discovery Studio® product line. To read article click here. Accelrys Inc. provides software packages for molecular modeling, drug discovery, life science, material science, combinatorial chemistry and high-throughput screening. For a review of Accelrys' software packages here at CombiChem Lab click here.

Scientists from Nymox Pharmaceutical Corporation discover spherotoxin molecule class play a key role in the Alzheimer's disease process. To read article click here.

QTL Biosystems introduces the QTL LIGHTSPEED™ Beta-Secretase Assay Kit. To read article click here.

Perlegen Sciences Inc. expands pharmacogenomics research collaboration with Eli Lilly and Company. To read article click here.

Structural GenomiX Inc. and Boehringer Ingelheim Pharmaceuticals Inc. expand lead optimization-drug discovery research collaboration. To read article click here.

Cytochroma Inc. select CTA018 as a drug candidate for the treatment of mild to moderate psoriasis. To read article click here.

-9/22/2003-

Press Release: Genevac Ltd., a supplier of lab equipment and supplies for solvent evaporation applications, has announced the launch of its updated and expanded website. To read press release click here. Genevac Ltd. provides high-throughput centrifugal evaporation systems for combinatorial chemistry, high-throughput screening (HTS) and drug discovery. To read a review of Genevac's systems here at CombiChem Lab click here.

Press Release: Available from INTEGRA Biosciences the MediaClave nutrient media preparator and steriliser guarantees the gentle and rapid preparation of standard and highly sensitive nutrient media for medical and microbiological laboratories. To read press release click here.

Cambridge Antibody Technology and Dyax Corp. expand licensing agreement. To read article click here. Biotage Inc., a division of Dyax Corp., has a broad variety of purification systems for drug discovery. To find a review of Biotage's purification systems here at CombiChem Lab click here.

Boston Life Sciences Inc.'s President and CEO resigns. To read article click here.

Receptor BioLogix Inc. licenses parts of its technology to Incyte Corp. for Incyte's small-molecule cancer program. To read article click here.

United Therapeutics Corp.'s drug Remodulin not appoved in France. To read article click here.

Sucampo Pharmaceuticals Inc. initiates Phase IIa safety clinical trials of agent SPI-8811 for Cystic Fibrosis (CF) treatment. To read article click here.

Applied Molecular Evolution Inc. opens new state-of-the-art bioprocessing facility. To read article click here.

Elan Corporation teminates joint venture with Depomed Inc. To read article click here.

SEQUENOM Inc. introduces the MassARRAY™ Compact system for DNA analysis. To read article click here.

Cambridge Antibody Technology and Genzyme Corporation extend human monoclonal antibody collaboration targeting TGF-beta. To read article click here.

BioMarin Pharmaceutical Inc. stops Phase 3a study of Neutralase™ and terminates its development. To read article click here.

Myriad Proteomics Inc. changes its name to Prolexys Pharmaceuticals Inc. To read article click here.

GlaxoSmithKline licenses part of Ingenuity Systems's Ingenuity Pathways Knowledge Base. To read article click here.

ChemCodes Inc. and Hoffmann-la Roche Inc. complete successfully drug discovery collaboration. To read article click here.

MDS Pharma Services and Iconix Pharmaceuticals Inc. launch chemogenomics profiling service for drug candidates: Pharmotif™ Solutions. To read article click here.

Alnylam Pharmaceuticals Inc. in-licenses RNA interference technology from Stanford University. To read article click here.

FDA grants GPC Biotech AG's drug Satraplatin fast track status for hormone-refractory prostate cancer treatment. To read article click here.

-9/19/2003-

Press Release: Guava Technologies, Inc., specialists in cell based research tools, has announced that Kevin McCormack has joined the company as director of European operations. To read press release click here.

Transkaryotic Therapies Inc. begins clinical trials of iduronate-2- sulfatase for the treatment for Hunter syndrome. To read article click here.

Cellomics Inc. receives U.S. patent 6,620,591 entitled " System for cell-based screening." To read article click here.

Protein Design Labs Inc. and Genentech Inc. extend collaboration for another 5 years. To read article click here.

-9/18/2003-

IBC to host the "The Impact of Post-Translational & Chemical Modifications" conference on November 12-14, 2003, in Vienna, VA. For more information on this conference click here. IBC promotes and hosts a broad range of scientific oriented conferences. For more information on IBC here at CombiChem Lab click here.

Dendreon Corp. 's experimental prostate cancer drug Provenge failed to significantly delay prostate cancer progression. To read article click here.

Researchers at Peregrine Pharmaceuticals Inc. publish in the journal Cancer Research evidence that different antibody-based targeting agents are effective to elicit the coagulation protein truncated tissue factor (tTF) to tumors for the treatment of cancer. To read article click here.

Amersham Biosciences introduces the MegaBACE™ 4500 DNA sequence analyzer. To read article click here.

Roche Holding AG and Memory Pharamceuticals Corp. expand Alzheimer's and schizophrenia drugs alliance. To read article click here.

FDA approves Genta Inc.'s drug Ganite to control hypercalcemia (blood calcium) levels in patients with advanced cancer. To read article click here.

Graffinity Pharmaceuticals AG and Genentech Inc. form small-molecule therapeutics research collaboration. To read article click here.

Generex Biotechnology Corporation initiates Phase II-B trials of Oralin™ for Type 2 diabetes treatment. To read article click here.

Replidyne Inc. forms research collaborations with Array BioPharma and Sequoia Sciences. To read article click here.

-9/17/2003-

Press Release: Genevac announces its high performance Model HT-4X centrifugal evaporator to provide highly efficient, high throughput sample processing within limited bench space. To read press release click here. Genevac Ltd. provides high-throughput centrifugal evaporation systems for combinatorial chemistry, high-throughput screening (HTS) and drug discovery. To read a review of Genevac's systems here at CombiChem Lab click here.

Thermo Electron Corporation to acquire Jouan SA for $124 million. To read article click here. ThermoQuest-Finnigan, a division of Themo Corp., offers a wide line of LC/MS systems for analysis in diverse areas and applications of drugd discovery. For a review of ThermoQuest-Finnigan's LC/MS systems here at CombiChem Lab click here. Jouan offers a line of rotors and evaporators for high-throughput applications. For more information about Jouan here at CombiChem Lab click here.

Corixa Corp. initiates Phase I clinical study of an investigational vaccine for Non Small Cell Lung Cancer (NSCLC) treatment. To read article click here.

Novasite Pharmaceuticals Inc. receives 3 SBIR grants for the crystallization of 3 G-protein coupled receptors (GPCRs): Serotonin, Cannabinoid and EDG. To read article click here.

FDA grants fast-track status to Introgen Therapeutics Inc.'s Advexin for head and neck cancer treatment. To read article click here.

CytRx Corporation forms Araios Inc. to develop small-molecule orally active drugs for obesity and type II diabetes treatment. To read article click here.

Sigma-Genosys and Compugen Ltd. release a human OligoLibrary™ covering approximately 29,000 oligonucleotide probes. To read article click here.

Elan Corp.'s sales drop 46%. To read article click here.

Epoch Biosciences Inc. licenses its Eclipse™ Dark Quencher technology to Applied Biosystems. To read article click here.

-9/16/2003-

The Strategic Research Institute (SRI) will host the "Angiogenesis: New Opportunities & Solutions for Drug Development" conference on September 29-30, 2003, in Cambridge, MA. To read article click here. SRI promotes and hosts a broad range of scientific oriented conferences. For more information on SRI here at CombiChem Lab click here.

GEMA Biotech announces the successful use of Accelrys Inc.'s Discovery Studio® to accelerate and prioritize drug discovery efforts. To read article click here. Accelrys Inc. provides software packages for molecular modeling, drug discovery, life science, material science, combinatorial chemistry and high-throughput screening. For a review of Accelrys' software packages here at CombiChem Lab click here.

Bristol-Myers Squibb wins patent litagation against Repligen Corp. on protein CTLA4 involved in the body's immune system. Repligen Corp. licensed the patents in question from the University of Michigan. To read article click here.

Repligen Corporation is granted patent covering the use of CTLA4-Ig for the treatment of rheumatoid arthritis. This patent is not affected byt the patent litigation won by Bristol-Myers Squibb. To read article click here.

Iconix Pharmaceuticals Inc.'s DrugMatrix™ library includes more than 250 highly specific well validated signatures. To read article click here.

Roche and ParAllele BioScience form research collaboratation to study genetic basis of diabetes. To read article click here.

Pharmaceutical Resources Inc. appoints Scott Tarriff as President and CEO. To read article click here.

Atrix Laboratories Inc. terminates joint venture with Elan Corp. To read article click here.

Genelabs Technologies Inc.'s antifungal compound GL48656 effective against systemic Aspergillus fungal infections in mice models. To read article click here.

-9/15/2003-

Press Release: Tecan (UK) has announced a new 384-channel pipetting head incorporating proprietary liquid displacement technology that offers superior precision and prevention of cross contamination. To read press release click here. Tecan provides the ChemSystem workstation and the TECAN MiniPrep systems for combinatorial chemistry and drug discovery. To read a review of TECAN's systems here at CombiChem Lab click here.

Press Release: Tecan (UK) has announced the availability of issue 2 of its global newsletter for researchers involved or considering using laboratory automation. To read press release click here. Tecan provides the ChemSystem workstation and the TECAN MiniPrep systems for combinatorial chemistry and drug discovery. To read a review of TECAN's systems here at CombiChem Lab click here.

Press Release: A new applications note from ESA describes and illustrates how HPLC with coulometric array detection can be used for the measurement of xenoestrogens - a diverse group of compounds found in the environment that mimic the effects of endogenous estrogens. To read press release click here.

Press Release: Drawing upon the experience of installing over 300 instruments for picking and placing in leading scientific institutions, Genetix Ltd. has announced the launch of the ClonePix - the world's first commercial automated mammalian cell colony picker. To read press release click here.

Cyanotech Corporation subject to be deslisted from Nasdaq. To read article click here.

Genzyme Corp. acquires the SangStat Medical Corp. for about $600 million. To read article click here.

Generex Biotechnology receives SBIR grant melanoma peptide vaccine. To read article click here.

Researchers at Rigel Pharmaceuticals publish in in the Journal of Biology the discovery of novel T-cell receptor signaling regulators involved in the immune response system. To read article click here.

Bayer AG and Paratek Pharmaceuticals Inc. form collaboration for the development of aminomethylcycline antibiotic BAY 73-6944/PTK 0796. To read article click here.

Court finds that Natural Biologics misappropriated trade secrets from Wyeth. To read article click here.

Althea Technologies Inc. receives U.S. patent 6,618,679 covering its eXpress Profiling™ technology entitled "Methods for Analysis of Gene Expression." To read article click here.

-9/12/2003-

The Strategic Research Institute (SRI) will host the "Oncology & Antibody Business Development Global Summit" conference on October 20-21, 2003, in Philadelphia, PA. To read article click here. SRI promotes and hosts a broad range of scientific oriented conferences. For more information on SRI here at CombiChem Lab click here.

FDA approves Cubist Pharmaceuticals Inc.'s Cubicin (Cidecin) for the trerament of skin and skin-structure infections. To read article click here.

Chimerix Inc. lincenses Gilead Sciences Inc.'s cidofovir smallpox treatment. To read article click here.

Eyetech Pharmaceuticals Inc. goes public. To read article click here.

SCYNEXIS Inc. and Roche extend CNS and Metabolic Disease research collaboration. To read article click here.

-9/11/2003-

The Center for Pharmaceutical Training will present the "FDA's Quality Systems Approach" conference on October 27-29, 2003, in Washington, DC. To read article click here.

Genaissance Pharmaceuticals Inc. and AstraZeneca Plc sign cholesterol deal. To read article click here.

Researchers at Curis Inc. publish in the journal Neuron evidence that the Hedgehog signaling pathway is required in the brain progenitor cell process. To read article click here.

Access Pharmaceuticals Inc. and the Celltech Group plc form oral drug delivery research collaboration. To read article click here.

Thomson ISI ResearchSoft releases RefViz™ to analize visually reference literature and it is compatible with EndNote®, ProCite® and Reference Manager®. To read article click here.

Zyomyx Inc. recieves U.S. patents 6,582,969 and 6,596,545 for covering a method and device for the screening of biomolecular activity. To read article click here.

-9/10/2003-

Argonaut Technologies Inc. releases its 2003-2004 Synthesis and Purification Catalog. To read article click here. Argonaut Technologies provides chemical and reagents as well as semiautomated synthesizers for parallel synthesis. For a review of Argonaut Technologies' chemicals and semiautomated synthesizers here at CombiChem Lab click here and here, respectively.

Tripos Inc. releases its SYBYL® application suite on HP Integrity servers and Intel Itanium-based workstations running the HP-UX operating system. To read article click here. Tripos Inc. provides a suite of software tools for combinatorial chemistry and drug discovery. For a review of Tripos' software tools here at CombiChem Lab click here.

Bayer AG settles 1,342 Baycol cases for $477 million. To read article click here.

Rigel Pharmaceuticals Inc. moves its compound R112 for allergic rhinitis to safety trials. To read article click here.

RNAi News: First publication to focus on RNA interference. To read article click here.

InNexus Biotechnology Inc. and Corixa Corporation form antibody research collaboration. To read article click here.

Atto Bioscience Inc. acquires Cytoprint Inc. To read article click here.

AVI BioPharma Inc. initiates antisense clinical trials of Neugene against West Nile virus. To read article click here.

Panacea Pharmaceuticals Inc. and MIT extend oncology research collaboration. To read article click here.

Applied Molecular Evolution Inc. initiates Phase II clinical trials for Vitaxin in both cancer and rheumatoid arthritis. To read article click here.

Evotec OAI and DeveloGen form obesity and diabetes drug discovery collaboration. To read article click here.

Celgene Corp. receives two patents for its JNK program targeting cancer, metabolic, immune and inflammatory diseases. To read article click here.

Biopure Corporation and the Veterinary Emergency and Critical Care Society establish the Saxon Service Dog Award and the Oxyglobin K-9 Alliance Program. To read article click here.

-9/09/2003-

The Strategic Research Institute (SRI) will host the "10th Annual Ethnic Marketing Omnibus" conference on September 30 - October 2, 2003, in Chicago, IL. To read article click here. SRI promotes and hosts a broad range of scientific oriented conferences. For more information on SRI here at CombiChem Lab click here.

The Strategic Research Institute (SRI) will host the "3rd Annual Pharma & Biotech Business Intelligence Summit" conference on September 18-19, 2003, in Princeton, NJ. To read article click here. SRI promotes and hosts a broad range of scientific oriented conferences. For more information on SRI here at CombiChem Lab click here.

FDA advisory comittee backs Genentech Inc.'s and XOMA Ltd.'s Raptiva™ (Efalizumab) for the treatment of moderate-to-severe plaque psoriasis. To read article click here.

Former Schering-Plough Corp.'s CEO Richard Kogan settles SEC charges. To read article click here.

Regeneron Pharmaceuticals to move AXOKINE® to Phase III trials for obesity treatment. To read article click here.

MedImmune Inc. to intiate two Phase 2 clinical trials for Vitaxin for metastatic melanoma and rheumatoid arthritis treatment. To read article click here.

Aphios Corporation receives Phase I SBIR grant for the "Development of Novel Anti-Smallpox Therapeutics from Marine Microorganisms." To read article click here.

OncoGenex Technologies Inc. and Isis Pharmaceuticals Inc. expand antisense drug-development partnership. To read article click here.

GeneMax Corp. and Molecular Medicine BioServices Inc. form alliance for the production of TAP cancer vaccine. To read article click here.

Merck & Co. and Alnylam Holding Co. form collaboration to develop RNAi-based technology and therapeutics. To read article click here.

Chimerix Inc. receives $36.1 million grant from the U.S. National Institute of Allergy and Infectious Diseases to develop an oral antiviral drug for the treatment of smallpox infections. To read article click here.

-9/08/2003-

Press Release: Guava Technologies' has announced that Life Science researchers can accelerate their research by detecting cell health earlier using their unique ViaCount assay. To read press release click here.

The Strategic Research Institute (SRI) will host the "8th Drug Delivery Technologies & Deal-Making Summit" conference on September 15-17, 2003, in Cherry Hill, NJ. To read article click here. SRI promotes and hosts a broad range of scientific oriented conferences. For more information on SRI here at CombiChem Lab click here.

Accelrys Inc. releases Accord Enterprise Informatics 5.3 and DS Accord for Excel Enterprise. To read article click here. Accelrys Inc. provides software packages for molecular modeling, drug discovery, life science, material science, combinatorial chemistry and high-throughput screening. For a review of Accelrys' software packages here at CombiChem Lab click here.

Accelrys Inc. launhces DS Modeling 1.2 - SBD: Structure-Based Design Tools for Drug Discovery. To read article click here. Accelrys Inc. provides software packages for molecular modeling, drug discovery, life science, material science, combinatorial chemistry and high-throughput screening. For a review of Accelrys' software packages here at CombiChem Lab click here.

Tripos Inc. releases SYBYL® 6.9.1/UNITY® 4.4.1. To read article click here. Tripos Inc. provides a suite of software tools for combinatorial chemistry and drug discovery. For a review of Tripos' software tools here at CombiChem Lab click here.

ArQule Inc. completes the acquisition of Cyclis Pharmaceuticals Inc. To read article click here. ArQule Inc provides its services for combinatorial chemistry and drug discovery. For a review of ArQule's discovery services here at CombiChem Lab click here.

Researchers at the Stanford University School of Medicine discover that an enhanced bacteria in the body prevents HIV infections in women. To read article click here.

Amgen Inc. to pay up to $612 million for Biovitrum AB's rights to experimental drugs for Type 2 diabetes and other metabolic disorders. To read article click here.

Aventis SA and Regeneron Pharmaceuticals Inc. sign $510 million anti-cancer deal centering on Vascular Endothelial Growth Factor (VEGF) Trap. To read article click here.

FDA approves Epeius Biotechnologies Corporation 's orphan drug REXIN-G for pancreatic cancer. To read article click here.

Teva Pharmaceutical Industries Ltd. submitts to the FDA a New Drug Application (NDA) for rasagiline for the treatment of Parkinson's disease (PD). To read article click here.

Incyte Corporation and Pharmasset Ltd. form HIV collaboration for a Phase II study of the antiretroviral drug Reverset™ (RVT, D-D4FC or DPC-817). To read article click here.

StemCells Inc. receives $342,000 SBIR grant from the National Institute of Neurological Disease and Stroke (NINDS) to develop human neural stem cells for spinal cord injuries treatment. To read article click here.

-9/05/2003-

Andrx Corp. settles Glucotrol XL dispute with Pfizer Inc. To read article click here.

Diversa Corporation receives U.S. patent 6,610,528 covering technologies directed to microbial enrichment for discovery of novel molecules from the environment. To read article click here.

-9/04/2003-

The Strategic Research Institute (SRI) will host the "Oncology & Antibody Business Development Global Summit" conference on October 20-21, 2003, in Philadelphia, PA. To read article click here. SRI promotes and hosts a broad range of scientific oriented conferences. For more information on SRI here at CombiChem Lab click here.

Pharmacopeia Inc. and Schering-Plough Corp. form drug discovery research collaboration. To read article click here. Pharmacopeia Inc. provides services for drug discovery R&D. For a review of Pharmacopeia's services here at CombiChem Lab click here.

ArQule Inc. and Novartis Institutes for BioMedical Research Inc. form chemistry collaboration. To read article click here. ArQule Inc provides its services for combinatorial chemistry and drug discovery. For a review of ArQule's discovery services here at CombiChem Lab click here.

FDA grants fast-track status to Dendreon Corp.'s prostate-cancer vaccine Provenge. To read article click here.

ProteoTech Inc. receives U.S. patent 6,607,758 entitled "Methods for Inhibiting and Reducing Amyloid Fibril Formation Associated with Alzheimer's Disease and Other Amyloidoses." To read article click here.

Researchers at Boston Life Sciences Inc. and Boston Children's Hospital identify carbohydrates that stimulate optic nerve regeneration. To read article click here.

-9/03/2003-

The Strategic Research Institute (SRI) will host the "Outsourcing of Clinical Drug Development" conference on September 15-17, 2003, in Scottsdale, AZ. To read article click here. SRI promotes and hosts a broad range of scientific oriented conferences. For more information on SRI here at CombiChem Lab click here.

Epimmune Inc. cuts 23% of its work force. To read article click here.

Epimmune Inc. licenses its PADRE® technology to Amgen Inc. for research. To read article click here.

FDA suspends Antigenics Inc.'s cancer vaccine trials. To read article click here.

Shire Pharmaceuticals Group files lawsuit against Barr Laboratories Inc. for infringement Shire Laboratories' U.S. patent No. 6,605,300. To read article click here.

Cangene and Acambis form collaboration for West Nile virus treatment. To read article click here.

Structural GenomiX Inc. and OSI Pharmaceuticals Inc. form research collaboration. To read article click here.

Quorex Pharmaceuticals Inc. and IDEC Pharmaceutical Corporation form research collaboration. To read article click here.

FDA grants fast-track status to Telik Inc.'s Telcyta™ for ovarian cancer treatment. To read article click here.

-9/02/2003-

Discovery Partners International Inc. (DPII) and Kyorin Pharmaceutical Co. form drug discovery collaboration. To read article click here. DPII has 2 subsidiaries, ChemRx and IRORI, to provide support to drug discovery. ChemRx offers a diverse set of services for combinatorial chemistry and drug discovery. For a review of ChemRx's services here at CombiChem Lab click here. IRORI offers its radio-frequency tagged product line for combinatorial chemistry. For a review on IRORI's Accutag system here at CombiChem Lab click here.

Cima Labs Inc. rejects Cephalon Inc.'s $384 million takeover bid. To read article click here.

AVI BioPharma Inc.'s acquisition of Exegenics Inc. falls through. To read article click here.

-9/02/2003-

Labor day holiday in the USA. No news today.